Efficacy and safety of CAR T‐cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition

Documenti analoghi

• 669 | FEASIBILITY OF 2ND‐LINE CAR‐T CELL THERAPY AFTER EARLY FAILURE OF POLATUZUMAB‐CONTAINING 1ST‐LINE CHEMOIMMUNOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA
  di: M. Schubert, et al.
  Pubblicazione: (2025)
• Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party
  di: Philipp Berning, et al.
  Pubblicazione: (2025)
• Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee
  di: Nick van Sinderen, et al.
  Pubblicazione: (2025)
• Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH &G Committee
  di: Gandhi Damaj, et al.
  Pubblicazione: (2025)
• 337 | ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: AN ANALYSIS FROM THE EBMT LYMPHOMA WORKING PARTY
  di: I. Age Kos, et al.
  Pubblicazione: (2025)